Dr. David Feifel is a neuropsychiatrist and neuroscientist. He is currently Professor Emeritus of Psychiatry, UC San Diego, School of Medicine and President of Kadima Neuropsychiatry Institute in La Jolla, California.
‍
Dr. Feifel earned a B.Sc., M.A., M.D and a Ph.D. (Neurobiology) from the University of Toronto where he also completed an internship in Internal Medicine. He then completed a psychiatry residency at UC San Diego, serving as chief resident in his senior year. After residency, he was recruited to the faculty of UCSD’s Department of Psychiatry, subsequently rising to rank of full professor.
‍
At UCSD, Dr. Feifel headed the Neuropsychiatry and Behavioral Medicine Program, established the UCSD Adult ADHD program, and founded the Center for Advanced Treatment of Mood and Anxiety Disorders (CATMAD), where he introduced several innovative treatments such as transcranial magnetic stimulation (TMS) and ketamine therapy. While at UCSD, Dr. Feifel also headed a, NIMH-funded, translational research program focusing on discovering new treatments for mental illness.
‍
In 2017, Dr. Feifel established Kadima Neuropsychiatry Institute, which is devoted to developing and providing cutting edge treatments for neuropsychiatric disorders. Among the current projects at Kadima are phase II & III clinical trials of psilocybin (Compass Pathways), LSD (Minded) and 5-MeO-DMT (Beckley Psytech) and “Project Africa,” helping health officials in Rwanda establish advanced treatment clinics modeled after Kadima.
‍
Addition distinctions include:
‍

• Authored or co-authored approximately 150 peer-reviewed scientific papers.
• Founded the world’s first ketamine infusion program for mental illness in 2008.
• Professional work has been featured in: New York Times, Time magazine, National Public Radio, USA Today, Scientific America, and Popular Science, among others.
• Diplomate of the American Board of Psychiatry and Neurology in General Psychiatry (APBN).
• United Council of Neurological Subspecialties (UCNS) certification in Behavioral Neurology and Neuropsychiatry.
• Peer-elected for inclusion in ‘Best Doctors in America’; One of five San Diego psychiatrists (as of 2023) included in Castle Connolly ‘Top Doctors’.
• Elected member, American College of Neuropsychopharmacology (ACNP).
• Current board member of the Clinical TMS Society and former co-chair of that organization’s Clinical Standards Committee.
• Member of National Network of Depression Centers (NNDC) task forces for: ketamine therapy; neuromodulation; psychedelic therapy; and treatment resistant depression.
• Expert Faculty, American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3)

‍
For more information on Kadima Neuropsychiatry Institute visit: https://www.kadimanp.com/